Brentuximab vedotin in relapse/refractory HL and ALCL among pediatric patients
Keywords:
Brentuximab vedotin, relapse, refractory, Hodgkin lymphoma, anaplastic large cell lymphoma, pediatricAbstract
Background: While adult patients with relapse or refractory (R/R) CD30+ lymphoma can be successfully treated with brentuximab vedotin (BV), an anti-CD30 monoclonal antibody, clinical results in pediatric patients are scarce. Here, we report the outcomes of children with R/R CD30+ lymphoma treated with BV. Methods: Patients with R/R treated with a BV-based regimen were retrospectively included. This was a BV intravenous drip for 1 hr on day 1, 1.4 mg/kg at first dose, titrated up to 1.8 mg/kg in subsequent doses every 21 days, combined with chemotherapy. Those with complete response (CR) underwent autologous hematopoietic stem cell (autoHSCT) transplant, followed by 16 courses of BV monotherapy as a maintenance therapy. Results: Of all 6 patients, 4 had Hodgkin lymphoma (HL), and 2 had anaplastic large cell lymphoma (ALCL). Median age at diagnosis was 12.3 (6.6-13.4) years. Four patients (3 HL, 1 ALCL) achieved CR and subsequently underwent autoHSCT with the median dose to CR of 3 (2-4); the other 2 patients attained partial response. All received maintenance monotherapy BV, without evidence of relapse: total median BV doses being 12 (6-16). Pancreatitis grade 3 was observed in 1 patient in the third BV course. Nontuberculous mycobacterial infection was diagnosed in the 1 patient in the fifth BV course. Conclusion: As a salvage treatment for CD30+ lymphoma in children, BV appears to show promise, but a larger cohort is warranted to better elucidate the clinical outcomes.
Downloads
References
Sherief LM, Elsafy UR, Abdelkhalek ER, Kamal NM, Elbehedy R, Hassan TH, et al. Hodgkin lymphoma in childhood: clinicopathological
features and therapy outcome at 2 centers from a developing country. Medicine (Baltimore). 2015;94:e670.
Akhtar S, Rauf SM, Elhassan TA, Maghfoor I. Outcome analysis of high-dose chemotherapy and autologous stem cell transplantation
in adolescent and young adults with relapsed or refractory Hodgkin lymphoma. Ann Hematol. 2016;95:1521-35.
Shankar A, Hayward J, Kirkwood A, McCarthy K, Hewitt M, Morland B, et al. Treatment outcome in children and adolescents with relapsed Hodgkin lymphoma--results of the UK HD3 relapse treatment strategy. Br J Haematol. 2014;165:534-44.
Bartlett NL, Niedzwiecki D, Johnson JL, Friedberg JW, Johnson KB, van Besien K, et al. Gemcitabine, vinorelbine, and pegylated
liposomal doxorubicin (GVD), a salvage regimen in relapsed Hodgkin’s lymphoma: CALGB 59804. Ann Oncol. 2007;18:1071-9.
Marr K, Ronsley R. Ifosfamide, gemcitabine, and vinorelbine is an effective salvage regimen with excellent stem cell mobilization in relapsed or refractory pediatric Hodgkin lymphoma. Pediatr Blood Cancer. 2020 Apr;67(4):e28167.
Le Deley MC, Rosolen A, Williams DM, Horibe K, Wrobel G, Attarbaschi A, et al. Vinblastine in children and adolescents with high-risk anaplastic large-cell lymphoma: results of the randomized ALCL99-vinblastine trial. J Clin Oncol. 2010;28:3987-93.
Brugieres L, Le Deley MC, Rosolen A, Williams D, Horibe K, Wrobel G, et al. Impact of the methotrexate administration dose on the need for intrathecal treatment in children and adolescents with anaplastic large-cell lymphoma: results of a randomized trial of the EICNHL Group. J Clin Oncol. 2009;27:897-903.
Woessmann W, Zimmermann M, Lenhard M, Burkhardt B, Rossig C, Kremens B, et al. Relapsed or refractory anaplastic large-cell lymphoma in children and adolescents after Berlin-Frankfurt-Muenster (BFM)-type first-line therapy: a BFM-group study. J Clin Oncol. 2011;29:3065-71.
Brugieres L, Pacquement H, Le Deley MC, Leverger G, Lutz P, Paillard C, et al. Single-drug vinblastine as salvage treatment for refractory or relapsed anaplastic large-cell lymphoma: a report from the French Society of Pediatric Oncology. J Clin Oncol. 2009;27:5056-61.
Francisco JA, Cerveny CG, Meyer DL, Mixan BJ, Klussman K, Chace DF, et al. cAC10-vcMMAE, an anti-CD30-monomethyl auristatin E conjugate with potent and selective antitumor activity. Blood. 2003;102:1458-65.
Broccoli A, Argnani L, Botto B, Corradini P, Pinto A, Re A, et al. First salvage treatment with bendamustine and brentuximab
vedotin in Hodgkin lymphoma: a phase 2 study of the Fondazione Italiana Linfomi. Blood Cancer J. 2019;9:100.
Cole PD, McCarten KM, Pei Q, Spira M, Metzger ML, Drachtman RA, et al. Brentuximab vedotin with gemcitabine for paediatric and young adult patients with relapsed or refractory Hodgkin’s lymphoma (AHOD1221): a Children’s Oncology Group, multicentre single-arm, phase 1-2 trial. Lancet Oncol. 2018;19:1229-38.
Pro B, Advani R, Brice P, Pinelli JM, Kennedy DA, Shustov A. Five-year results of brentuximab vedotin in patients with relapsed or refractory systemic anaplastic large cell lymphoma. Blood. 2017;130:2709-17.
Broccoli A, Pellegrini C, Di Rocco A, Puccini B, Patti C, Gini G, et al. Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma. Haematologica. 2017;102:1931-5.
Tebbi CK, Mendenhall NP, London WB, Williams JL, Hutchison RE, Fitzgerald TJ, et al. Response-dependent and reduced treatment
in lower risk Hodgkin lymphoma in children and adolescents, results of P9426: a report from the Children’s Oncology Group. Pediatr Blood Cancer. 2012;59:1259-65.
Kelly KM, Cole PD, Pei Q, Bush R, Roberts KB, Hodgson DC, et al. Response-adapted therapy for the treatment of children with newly diagnosed high risk Hodgkin lymphoma (AHOD0831): a report from the Children’s Oncology Group. Br J Haematol. 2019 Oct;187(1):39-48.
Sandlund JT, Pui CH, Mahmoud H, Zhou Y, Lowe E, Kaste S, et al. Efficacy of high-dose methotrexate, ifosfamide, etoposide and dexamethasone salvage therapy for recurrent or refractory childhood malignant lymphoma. Ann Oncol. 2011;22:468-71.
Wrobel G, Mauguen A, Rosolen A, Reiter A, Williams D, Horibe K, et al. Safety assessment of intensive induction therapy in childhood anaplastic large cell lymphoma: report of the ALCL99 randomised trial. Pediatr Blood Cancer. 2011;56:1071-7.
Kanoun S, Rossi C, Casasnovas O. [18F]FDG-PET/CT in Hodgkin Lymphoma: Current Usefulness and Perspectives. Cancers. 2018;10:145.
Sharma A, Kayal S, Iqbal S, Malik PS, Raina V. Comparison of BEAM vs. LEAM regimen in autologous transplant for lymphoma at AIIMS. SpringerPlus. 2013;2:489.
Gorde-Grosjean S, Oberlin O, Leblanc T, Pacquement H, Donadieu J, Lambilliotte A, et al. Outcome of children and adolescents with recurrent/refractory classical Hodgkin lymphoma, a study from the Société Française de Lutte contre le Cancer des Enfants et des Adolescents (SFCE). Br J Haematol. 2012;158:649-56.
Metzger ML, Hudson MM, Krasin MJ, Wu J, Kaste SC, Kun LE, et al. Initial response to salvage therapy determines prognosis in relapsed pediatric Hodgkin lymphoma patients. Cancer. 2010;116:4376-84.
Keller FG, Castellino SM, Chen L, Pei Q, Voss SD, McCarten KM, et al. Results of the AHOD0431 trial of response adapted therapy and a salvage strategy for limited stage, classical Hodgkin lymphoma: a report from the Children’s Oncology Group. Cancer. 2018;124:3210-9.
O’Connor OA, Lue JK, Sawas A, Amengual JE, Deng C, Kalac M, et al. Brentuximab vedotin plus bendamustine in relapsed or refractory Hodgkin’s lymphoma: an international, multicentre, single-arm, phase 1-2 trial. Lancet Oncol. 2018;19:257-66.
Chen R, Gopal AK, Smith SE, Ansell SM, Rosenblatt JD, Savage KJ, et al. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma. Blood. 2016;128:1562-6.
Mori T, Takimoto T, Katano N, Kikuchi A, Tabuchi K, Kobayashi R, et al. Recurrent childhood anaplastic large cell lymphoma: a retrospective analysis of registered cases in Japan. Br J Haematol. 2006;132:594-7.
Koga Y, Sekimizu M, Iguchi A, Kada A, Saito AM, Asada R, et al. Phase I study of brentuximab vedotin (SGN-35) in Japanese children with relapsed or refractory CD30-positive Hodgkin’s lymphoma or systemic anaplastic large cell lymphoma. Int J Hematol. 2020 May;111(5):711-718.
Locatelli F, Mauz-Koerholz C, Neville K, Llort A, Beishuizen A, Daw S, et al. Brentuximab vedotin for paediatric relapsed or refractory Hodgkin’s lymphoma and anaplastic large-cell lymphoma: a multicentre, open-label, phase 1/2 study. Lancet Haematol. 2018;5:e450-e61.
Chen C-C, Yeh S-P. Fatal pancreatitis occurred in a patient with refractory CD30+ anaplastic large cell lymphoma after brentuximab vedotin treatment. J Cancer Res and Prac. 2017;4:35-7.
Gandhi MD, Evens AM, Fenske TS, Hamlin P, Coiffier B, Engert A, et al. Pancreatitis in patients treated with brentuximab vedotin: a previously unrecognized serious adverse event. Blood. 2014;123:2895-7.
Pro B, Advani R, Brice P, Bartlett NL, Rosenblatt JD, Illidge T, et al. Brentuximab vedotin (SGN-35) in patients with relapsed or refractory systemic anaplastic large-cell lymphoma: results of a phase II study. J Clin Oncol. 2012;30:2190-6.
Bassetti M, Pecori D, Righi E, Brillo F, Cadeo B, Venturini S, et al. HSV-1 cutaneous infection in a patient with Hodgkin’s lymphoma treated with brentuximab vedotin. J Chemother. 2013;25:381-2.
Maschmeyer G, De Greef J, Mellinghoff SC, Nosari A, Thiebaut- Bertrand A, Bergeron A, et al. Infections associated with immunotherapeutic and molecular targeted agents in hematology and oncology. a position paper by the European Conference on Infections in Leukemia (ECIL). Leukemia. 2019;33:844-62.
Mukkada S, Metzger ML, Santiago T, Wolf J. Severe Progressive Mycobacterium avium Complex Infection Associated With Brentuximab Vedotin Therapy. J Pediatric Infect Dis Soc. 2019 Sep 25;8(4):371-373.
Downloads
Published
Issue
Section
License
Copyright (c) 2022 Journal of Hematology and Transfusion Medicine
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
